Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2019

View Archived Issues

CJ-15314: a novel JAK1 inhibitor for the treatment of rheumatoid arthritis

A-166, a new anti-HER2 antibody-drug conjugate for advanced/metastatic solid tumors: phase I results

Lineage Cell Therapeutics provides update on phase I/IIa SCiStar study of OPC-1

Interim analysis of phase II data for licogliflozin in NASH

Preliminary phase I data presented for DCC-3014

Phase IIa data for IONIS-HBVRx in treatment-naive chronic HBV patients

STAT3-targeting PROTAC proof of principle for 'undruggables'

Novel PDX mouse models of gastric cancer

Effluent DcR2 is a new marker of peritoneal fibrosis in patients with peritoneal dialysis

Differentially expressed sncRNAs in patients with T1D at risk of progressive renal disease

Promising phase I/Ib data presented for the novel anti-CD73 antibody CPI-006

First placebo-controlled trial in renal scleroderma shows positive results for zibotentan

Fujifilm initiates phase I trial of FF-10850 in advanced solid tumors

Double-duty CD4+ T cells may hold key to longevity

3SBio and Verseau select VTX-0811 as first licensed program under immuno-oncology partnership

Phase II study of KarXT for acute psychosis in schizophrenia meets primary endpoint

Clinical study of [131I]omburtamab advances in desmoplastic small round cell tumors

A placebo-controlled, first-in-human phase I study of the anti-ADAMTS-5 nanobody M-6495

Janssen Pharmaceutica patents androgen receptor antagonists

Bristol-Myers Squibb divulges TLR7 agonists

Ribon Therapeutics describes TIPARP inhibitors

Landsteiner Genmed identifies CAPN1 inhibitors

Merck & Co. divulges nicotinic acetylcholine alpha7 receptor PAMs

U.K. clearance for phase I/II study of TX-200 in kidney transplantation

BioArctic to end SC-0806 development in complete spinal cord injury based on interim phase I/II data

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...